Iron tablets come in various formulations like ferrous sulfate, ferrous fumarate, ferrous gluconate, ferrous ascorbate, and ferrous bisglycinate. These supplements meet different needs for ...

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

The FDA has approved a tablet form of Livmarli (maralixibat) for cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.

New formulation provides patients with a simplified dosing experience-reducing pill burden and enhancing ease of administration-while preserving flexible dosing options BeOne Medicines Ltd. (NASDAQ: ...

The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib). The company formerly known as BeiGene announced ...

SAN CARLOS, Calif., June 11, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has ...

The new tablet formulation maintains BRUKINSA’s dosing flexibility by providing patients and prescribers with the option of once- or twice-daily dosing and is designed to simplify management of ...

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.

Iron tablets come in various formulations like ferrous sulfate, ferrous fumarate, ferrous gluconate, ferrous ascorbate, and ferrous bisglycinate. Thes ...

"The CHMP’s positive opinion of our new tablet formulation of BRUKINSA is an important step toward bringing this thoughtful, patient-centered innovation to people facing certain B-cell cancers ...